NCT06410703View on ClinicalTrials.gov

CAN1012 Combined With PD-1 in Patients With Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

CAN1012

CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W

Trial Locations (1)

510535

RECRUITING

Sun Yat-Sen University Sun Yat-Sen Memorial Hospital, Guangzhou

Sponsors
All Listed Sponsors
lead

Canwell Biotech Limited

INDUSTRY